Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2012 by Meir Medical Center.
Recruitment status was:  Available
Tel Aviv University
Information provided by (Responsible Party):
Meir Medical Center Identifier:
First received: December 27, 2010
Last updated: August 9, 2012
Last verified: August 2012
Recently the general medical literature has become aware that the use of certain long-acting insulin analogues could potentially increase cancer risk.During the last few years the investigators group generated information of both scientific and clinical relevance on the proliferative and anti-apoptotic actions of insulin analogues. The goal of this project is to evaluate the hypothesis that the proliferative and signalling activities elicited by insulin analogues may have a impact on tumor behavior. In this study the investigators will asses the biological actions of insulin analogs in primary tumor cells of endometrial and colon cancer.

Condition Intervention
Endometrial Cancer
Colon Cancer
Other: Tissue sample from tumor

Study Type: Expanded Access     What is Expanded Access?

Resource links provided by NLM:

Further study details as provided by Meir Medical Center:

Intervention Details:
    Other: Tissue sample from tumor
    Endometrial cancer specimens will be obtained from patients operated and treated at the Gynecologic Oncology Unit at Meir Medical Center. Colon cancer specimens will be obtained from patients that underwent colonoscopy at the Gastrointestinal Department at Meir Medical Center.

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Genders Eligible for Study:   Female

Inclusion Criteria:

  • Patients with Endometrial and Colon Cancer

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Meir Medical Center Identifier: NCT01267461     History of Changes
Other Study ID Numbers: 0015-10-MMC 
Study First Received: December 27, 2010
Last Updated: August 9, 2012
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Meir Medical Center:
To asses the biological actions of insulin analogs in primary tumor cells

Additional relevant MeSH terms:
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Genital Diseases, Female processed this record on December 09, 2016